Literature DB >> 11566555

Whole blood cytokine response as a measure of immunotoxicity.

I Langezaal1, S Coecke, T Hartung.   

Abstract

Immunotoxicity, although increasingly recognized as a potential hazard, still lacks standardized in vivo and in vitro models. The considerable species differences and species-specific effects in immune responses prompt the development of human in vitro test systems. Immunotoxic reactions comprise activation (inflammatory processes, autoaggressive processes, pyrogenicity), sensitization (priming, idiosyncratic reactions) and impairment of immune responses (anergy, immunosuppression). We have previously studied a human whole blood system which allows the study of the release of inflammatory cytokines in response to a variety of stimuli. This model allows the assessment of this basic immune mechanism without preparation artefacts and relatively small interindividual variances. We have used this model previously to assess pyrogens, namely type (1) immunotoxic reactions. The model also proved to be suitable for immunopharmacological studies in vitro as well as ex vivo. Here, we studied the suitability of the test system to study type (3) immunotoxic effects. In order to also allow ex vivo studies, we have transferred the system to murine blood. This report summarizes our own use of this model with special emphasis on immunotoxicological studies. Our own listed bibliography gives access to the variety of applications of the human whole blood model since its introduction in 1982.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566555     DOI: 10.1016/s0887-2333(01)00028-5

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

1.  Myelopeptides regulate the microbicidic and secretory activities of innate immunity effectors.

Authors:  V A Chereshnev; S V Gein; L S Mazunina; T V Gavrilova; M V Chereshneva
Journal:  Dokl Biochem Biophys       Date:  2011-03-04       Impact factor: 0.788

Review 2.  Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.

Authors:  Frank R Brennan; Laura Dill Morton; Sebastian Spindeldreher; Andrea Kiessling; Roy Allenspach; Adam Hey; Patrick Y Muller; Werner Frings; Jennifer Sims
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

Review 3.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  J Control Release       Date:  2013-06-03       Impact factor: 9.776

Review 4.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

5.  Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis.

Authors:  Stéphane Jouneau; Mélanie Bonizec; Chantal Belleguic; Benoit Desrues; Graziella Brinchault; Jeanne Galaine; Jean-Pierre Gangneux; Corinne Martin-Chouly
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

6.  Immunostimulatory effects of RACK1 pseudosubstrate in human leukocytes obtained from young and old donors.

Authors:  Emanuela Corsini; Valentina Galbiati; Antonella Pinto; Annalisa Davin; Letizia Polito; Antonio Guaita; Marco Racchi
Journal:  Oncotarget       Date:  2015-03-30

7.  A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA.

Authors:  Christoph Coch; Christian Lück; Anna Schwickart; Bastian Putschli; Marcel Renn; Tobias Höller; Winfried Barchet; Gunther Hartmann; Martin Schlee
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

8.  An international validation study of the IL-2 Luc assay for evaluating the potential immunotoxic effects of chemicals on T cells and a proposal for reference data for immunotoxic chemicals.

Authors:  Yutaka Kimura; Rie Yasuno; Mika Watanabe; Miwako Kobayashi; Tomoko Iwaki; Chizu Fujimura; Yoshihiro Ohmiya; Kohji Yamakage; Yoshihiro Nakajima; Mayumi Kobayashi; Nana Mashimo; Yumi Takagi; Takashi Omori; Emanuela Corsini; Dori Germolec; Tomoaki Inoue; Erwin L Rogen; Hajime Kojima; Setsuya Aiba
Journal:  Toxicol In Vitro       Date:  2020-03-18       Impact factor: 3.685

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.